Discovery & Development

During the COVID-19 pandemic, significant progress was made in improving clinical trials. But there are now signs of backsliding.

We explore how AI-based tools are making a mark in formulation by improving solubility.

A glimpse into the research of one of the most prevalent gastrointestinal disorders worldwide, and how small molecule drug development is helping.

Recent developments in the treatment of psoriasis has brought new hope to sufferers, and a surge in market standings.

We speak with experts from Amgen and Henry Ford Health about the development and approval of Uplizna for IgG4-related disease.

From different modalities to overcoming aggregation; we find out what advances are affecting the development of ADCs.

The FDA says it wants to phase out mandatory animal testing requirements for drug approval. What comes next?

As biologics become more complex, mass spec becomes more indispensable than ever in the drug developer’s toolbox.

Eli Lilly and Purdue University strengthen their ongoing drug discovery collaboration with further initiatives.

How new structural insights captured in high-resolution images could fuel next-gen therapies for TB.